\u767a\u520a\u6e08\u306e\u3082\u306e\u306fabstract\u307e\u305f\u306f\u672c\u6587\u306b\u30ea\u30f3\u30af\u3057\u3066\u3042\u308a\u307e\u3059\u3002
\nPublished papers are linked to PubMed<\/p>\n
<\/p>\n
Tamura S, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, Kusaba H, Takenaka K, Ueki T, Nakamura M, Akashi K, Baba E.<\/a><\/a>
\nMinagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.<\/a><\/a>
\nEnhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
\nCell Stem Cell. 2018 Dec 6;23(6):850-858.e4.<\/p>\n
\n
\n<\/p>\n
\nNabe S, Yamada T, Suzuki J, Toriyama K, Yasuoka T, Kuwahara M, Shiraishi A, Takenaka K, Yasukawa M, Yamashita M.<\/a><\/a>
\nReinforce the antitumor activity of CD8+ T cells via glutamine restriction.
\nCancer Sci. 2018 Dec;109(12):3737-3750. <\/p>\n
\n
\n<\/p>\n
\nIkeda Y, Yamanouchi J, Kumon Y, Yasukawa M, Hato T.<\/a><\/a>
\nAssociation of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.
\nThromb Res. 2018 Dec;172:14-20. <\/p>\n
\n
\n<\/p>\n
\nIkeda Y, Yamanouchi J, Hato T, Yasukawa M, Takenaka K.<\/a><\/a>
\nSafe childbirth for a type 1 antithrombin-deficient woman with novel mutation in the SERPINC1 gene undergoing antithrombin concentrate therapy.
\nBlood Coagul Fibrinolysis. 2018 Nov 13. <\/p>\n
\n
\n<\/p>\n
\nYamanouchi J, Tokumoto D, Ikeda Y, Maruta M, Kaneko M, Hato T, Yasukawa M.<\/a><\/a>
\nDevelopment of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation.
\nIntern Med. 2018 Nov 1;57(21):3179-3182. <\/p>\n
\n
\n<\/p>\n
\nKawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y.<\/a><\/a>
\nOlanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.
\nSci Rep. 2018 Nov 2;8(1):16232.<\/p>\n
\n
\n<\/p>\n
\nKawazoe H, Murakami A, Yamashita M, Nishiyama K, Kobayashi-Taguchi K, Komatsu S, Aoki R, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y.<\/a><\/a>
\nPatient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Retrospective Observational Study.
\nClin Ther. 2018 Nov 1. pii: S0149-2918(18)30495-8. <\/p>\n
\n
\n<\/p>\n
\nAkahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H.<\/a><\/a>
\nAntitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
\nBlood. 2018 Sep 13;132(11):1134-1145. <\/p>\n
\n
\n<\/p>\n
\nOgura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG).<\/a><\/a>
\nR-High-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
\nCancer Sci. 2018 Sep;109(9):2830-2840.<\/p>\n
\n
\n<\/p>\n
\nSuzuki J, Yamada T, Inoue K, Nabe S, Kuwahara M, Takemori N, Takemori A, Matsuda S, Kanoh M, Imai Y, Yasukawa M, Yamashita M.<\/a><\/a>
\nThe tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation.
\nNat Commun. 2018 Aug 17;9(1):3296. <\/p>\n
\n
\n<\/p>\n
\nE-cadherin regulates proliferation of colorectal cancer stem cells through NANOG.
\nOncol Rep. 2018 Aug;40(2):693-703.<\/p>\n
\n
\n<\/p>\n
\nSasaki K, Mori Y, Yoshimoto G, Sakoda T, Kato K, Inadomi K, Kamezaki K, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K.<\/a>
\nSuccessful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
\nLeuk Lymphoma. 2018 Aug;59(8):2005-2007. <\/p>\n
\n
\n<\/p>\n
\nYoshimoto G, Mori Y, Kato K, Shima T, Miyawaki K, Kikushige Y, Kamezaki K, Numata A, Maeda T, Takenaka K, Iwasaki H, Teshima T, Akashi K, Miyamoto T.<\/a><\/a>
\nHuman Herpes Virus-6-Associated Encephalitis\/Myelitis Mimicking Calcineurin Inhibitor-Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients.
\nBiol Blood Marrow Transplant. 2018 Jul 17. pii: S1083-8791(18)30404-X. <\/p>\n
\n
\n<\/p>\n
\nTakenaka K, Shimoda K, Akashi K.<\/a><\/a>
\nRecent advances in the diagnosis and management of primary myelofibrosis.
\nKorean J Intern Med. 2018 Jul;33(4):679-690. <\/p>\n
\n
\n<\/p>\n
\nMori Y, Yoshimoto G, Nishida R, Sugio T, Miyawaki K, Shima T, Nagasaki Y, Miyake N, Harada Y, Kunisaki Y, Kamezaki K, Numata A, Kato K, Shiratsuchi M, Maeda T, Takenaka K, Iwasaki H, Shimono N, Akashi K, Miyamoto T.<\/a><\/a>
\nGastrointestinal Graft-versus-Host Disease Is a Risk Factor for Postengraftment Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
\nBiol Blood Marrow Transplant. 2018 Jun 15. pii: S1083-8791(18)30314-8.<\/p>\n
\n
\n<\/p>\n
\nOkada M, Suemori K, Takagi D, Teraoka M, Yamada H, Ishizaki J, Matsumoto T, Hasegawa H, Hato N.<\/a><\/a>
\nThe treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis.
\nAuris Nasus Larynx. 2018 Jun 6. pii: S0385-8146(18)30161-5. <\/p>\n
\n
\n<\/p>\n
\nMori Y, Yoshimoto G, Yuda JI, Hayashi M, Odawara J, Kuriyama T, Sugio T, Miyawaki K, Kamezaki K, Kato K, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K.<\/a><\/a>
\nPrevious exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
\nLeuk Lymphoma. 2018 May 9:1-3.<\/p>\n
\n
\n<\/p>\n
\nIida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K.<\/a>
\nBortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
\nCancer Sci. 2018 May;109(5):1552-1561.<\/p>\n
\n
\n<\/p>\n
\nMuneishi M, Nakamura A, Tachibana K, Suemitsu J, Hasebe S, Takeuchi K, Yakushijin Y.<\/a>
\nRetrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.
\nInt J Clin Oncol. 2018 Apr;23(2):375-381.<\/p>\n
\n
\n<\/p>\n
\nKaneko M, Shikata H, Matsukage S, Maruta M, Shinomiya H, Suzuki T, Hasegawa H, Shimojima M, Saijo M.<\/a>
\nA patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system.
\nJ Infect Chemother. 2018 Apr;24(4):292-297. <\/p>\n
\n
\n<\/p>\n
\nHara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, Fujimoto S, Muso E, Kawakami T, Homma S, Yoshida M, Hirahashi J, Ogawa N, Ito S, Makino H, Arimura Y; Research Committee on Intractable Vasculitides, and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline.<\/a>
\nRisk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.
\nJ Rheumatol. 2018 Apr;45(4):521-528. <\/p>\n
\n
\n<\/p>\n
\nAnczurowski M, Yamashita Y, Nakatsugawa M, Ochi T, Kagoya Y, Guo T, Wang CH, Rahman MA, Saso K, Butler MO, Hirano N.<\/a><\/a>
\nMechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.
\nSci Rep. 2018 Mar 19;8(1):4804.<\/p>\n
\n
\n<\/p>\n
\nMuta T, Yoshihiro T, Jinnouchi F, Aoki K, Kochi Y, Shima T, Takenaka K, Ogawa R, Akashi K, Oshima K.<\/a><\/a>
\nExpansion of NKG2C-expressing Natural Killer Cells after Umbilical Cord Blood Transplantation in a Patient with Peripheral T-cell Lymphoma with Cytotoxic Molecules.
\nIntern Med. 2018 Mar 15;57(6):861-866. <\/p>\n
\n
\n<\/p>\n
\nEspinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Hassanein HA, Khalifa A Noreldin A, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S.<\/a><\/a>
\nHematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack.
\nBlood Adv. 2018 Feb 27;2(4):390-400.<\/p>\n
\n
\n<\/p>\n
\nIshida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R.<\/a>
\nFollow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
\nBr J Haematol. 2018 Feb 7.<\/p>\n
\n
\n<\/p>\n
\nCasey N, Fujiwara H, Azuma T, Murakami Y, Yoshimitsu M, Masamoto I, Nawa Y, Yamanouchi J, Narumi H, Yakushijin Y, Hato T, Yasukawa M.<\/a>
\nAn unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia\/lymphoma.
\nLeuk Lymphoma. 2018 Feb 21:1-3.<\/p>\n
\n
\n<\/p>\n
\nHasegawa H, Matsumoto T.<\/a>
\nMechanisms of Tolerance Induction by Dendritic Cells In Vivo.
\nFront Immunol. 2018 Feb 26;9:350.<\/p>\n
\n
\n<\/p>\n
\nMiyake N, Chong Y, Nishida R, Takenaka K, Kato K, Miyamoto T, Aono A, Takaki A, Mitarai S, Shimoda S, Shimono N, Akashi K.<\/a><\/a>
\nMycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
\nJ Infect Chemother. 2018 Jan;24(1):78-81. <\/p>\n
\n
\n<\/p>\n
\nKirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N.<\/a><\/a>
\nEvaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.
\nInt J Hematol. 2018 Jan;107(1):92-97.<\/p>\n
\n
\n<\/p>\n